(Q34849390)

English

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

1 reference

Europe PubMed Central

Review of the effect of highly active antiretroviral therapy on hepatitis C virus (HCV) RNA levels in human immunodeficiency virus and HCV coinfection (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

anti-retroviral agent

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

author name string

Curtis L Cooper

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

language of work or name

0 references

publication date

11 September 2002

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

Clinical Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

35

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

873-879

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12228825%20AND%20SRC:MED&resulttype=core&format=json

13 November 2019

Impact of human immunodeficiency virus infection on the histological features of chronic hepatitis C: a case-control study. The MULTIVIRC group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Serum HCV RNA levels assessed by quantitative NASBA: stability of viral load over time, and lack of correlation with liver disease. The Trent HCV Study Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Performance characteristics of the COBAS AMPLICOR hepatitis C virus MONITOR Test, version 2.0.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Comparative evaluation of hepatitis C virus RNA quantitation by branched DNA, NASBA, and monitor assays

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

A new step toward standardization of serum hepatitis C virus-RNA quantification in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Analysis of the viability of freezer stored serum samples for hepatitis C virus RNA analysis by the SUPERQUANT method: results of a 16 year retrospective study

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Impact of various handling and storage conditions on quantitative detection of hepatitis C virus RNA.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Stability of HCV-RNA level and its lack of correlation with disease severity in asymptomatic chronic hepatitis C virus carriers

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Sequential serum hepatitis C viral RNA levels longitudinally assessed by branched DNA signal amplification

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Evidence that both HIV and HIV-induced immunodeficiency enhance HCV replication among HCV seroconverters

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Low HCV replication levels in end-stage hepatitis C virus-related liver disease

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Serum HCV RNA levels correlate with histological liver damage and concur with steatosis in progression of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Liver damage and kinetics of hepatitis C virus and human immunodeficiency virus replication during the early phases of combination antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Human immunodeficiency virus (HIV) protease inhibitors have no effect on hepatitis C virus (HCV) serum levels of HIV-HCV co-infected patients

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Tritherapy for human immunodeficiency virus infection does not modify replication of hepatitis C virus in coinfected subjects

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease?

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Role of endogenous interferon in hepatitis C virus (HCV) infection and in coinfection by HIV and HCV.

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Sustained disappearance of hepatitis C viremia in patients receiving protease inhibitor treatment for human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Change in transaminases in hepatitis C virus- and HIV-coinfected patients after highly active antiretroviral therapy: differences between complete and partial virologic responders?

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Evolution of coinfection with human immunodeficiency virus and hepatitis C virus in patients treated with highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

1 reference

https://api.crossref.org/works/10.1086%2F342388

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34849390&oldid=1989427832"